A Study of Combination Therapy With Venetoclax, Daratumumab and Dexamethasone (With and Without Bortezomib) in Participants With Relapsed or Refractory Multiple Myeloma
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT03314181 |
Recruitment Status :
Active, not recruiting
First Posted : October 19, 2017
Last Update Posted : February 16, 2023
|
Sponsor:
AbbVie
Collaborator:
Janssen Research & Development, LLC
Information provided by (Responsible Party):
AbbVie
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
Recruitment Status : | Active, not recruiting |
---|---|
Estimated Primary Completion Date : | August 28, 2025 |
Estimated Study Completion Date : | August 28, 2025 |
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):